CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study.

@article{Seto2013CH5424802F,
  title={CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study.},
  author={Takashi Seto and Katsuyuki Kiura and Makoto Nishio and Kazuhiko Nakagawa and Makoto Maemondo and Akira Inoue and Toyoaki Hida and Nobuyuki Yamamoto and Hiroshige Yoshioka and Masao Harada and Yuichiro Ohe and Naoyuki Nogami and Kengo Takeuchi and Tadashi Shimada and Tomohiro Tanaka and Tomohide Tamura},
  journal={The Lancet. Oncology},
  year={2013},
  volume={14 7},
  pages={590-8}
}
BACKGROUND Currently, crizotinib is the only drug that has been approved for treatment of ALK-rearranged non-small-cell lung cancer (NSCLC). We aimed to study the activity and safety of CH5424802, a potent, selective, and orally available ALK inhibitor. METHODS In this multicentre, single-arm, open-label, phase 1-2 study of CH5424802, we recruited ALK inhibitor-naive patients with ALK-rearranged advanced NSCLC from 13 hospitals in Japan. In the phase 1 portion of the study, patients received… CONTINUE READING
Highly Influential
This paper has highly influenced 20 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
Recent Discussions
This paper has been referenced on Twitter 11 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 220 extracted citations

Similar Papers

Loading similar papers…